PMID- 33798808
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 96
DP  - 2021 Jul
TI  - The efficacy and safety of combination therapy with immune checkpoint inhibitors 
      in non-small cell lung cancer: A meta-analysis.
PG  - 107594
LID - S1567-5769(21)00230-7 [pii]
LID - 10.1016/j.intimp.2021.107594 [doi]
AB  - PURPOSE: Combination therapies with immune checkpoint blockade demonstrate 
      promising antitumor activity and safety in Non-small Cell Lung Cancer (NSCLC). 
      However, whether the combination therapy is superior to their monotherapies, and 
      which combination regimen is most efficacious remain unknown. This meta-analysis 
      aims to synthesize the current available evidences on the efficacy and safety of 
      combination immunotherapy in patients with NSCLC. METHODS: PubMed, Embase and 
      Cochrane Library were searched. Randomized controlled trials (RCTs) investigating 
      combination therapy with immune checkpoint inhibitors in NSCLC were included. 
      RESULTS: We identified nine RCTs including a total of 5,142 patients. The study 
      showed that the pooled hazard ratios (HRs) of overall survival (OS) and 
      progression-free survival (PFS) for combination therapy were 0.74 (95% CI: 
      0.63-0.86, p = 0.001) and 0.65 (95% CI: 0.56-0.73, p = 0.004); the pooled odds 
      ratios (ORs) of objective response rates (ORRs) and grade 3 or higher adverse 
      events (AEs) were 1.51 (95% CI: 1.02-1.99, p < 0.001) and 1.30 (95% CI: 
      1.03-1.57, p = 0.007). Subgroup analysis showed that the OR of grade 3 or higher 
      AEs for immunotherapy plus chemotherapy was higher than that of chemotherapy 
      alone, but did not reach statistical significance (p = 0.061) , and there was PFS 
      and OS benefit for either immunotherapy plus chemotherapy, double agent 
      immunotherapy or immunotherapy plus targeted plus chemotherapy combination 
      regimens. CONCLUSIONS: Combination therapy with immune checkpoint inhibitors 
      showed more clinical benefit for patients with NSCLC, with increased grade 3 or 
      higher AEs, but toxicities were manageable.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Mo, Dun-Chang
AU  - Mo DC
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China. Electronic address: 
      modunchang2018@163.com.
FAU - Huang, Jian-Feng
AU  - Huang JF
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
FAU - Luo, Peng-Hui
AU  - Luo PH
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
FAU - Huang, Shang-Xiao
AU  - Huang SX
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
FAU - Wang, Han-Lei
AU  - Wang HL
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20210330
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Combined Modality Therapy/adverse effects/methods
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*adverse effects/*therapeutic use
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Combination immunotherapy
OT  - Efficacy and safety
OT  - Immune checkpoint inhibitor
OT  - Meta-analysis
OT  - Non-small cell lung cancer
EDAT- 2021/04/03 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/04/02 20:18
PHST- 2021/02/01 00:00 [received]
PHST- 2021/03/10 00:00 [revised]
PHST- 2021/03/14 00:00 [accepted]
PHST- 2021/04/03 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/04/02 20:18 [entrez]
AID - S1567-5769(21)00230-7 [pii]
AID - 10.1016/j.intimp.2021.107594 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Jul;96:107594. doi: 10.1016/j.intimp.2021.107594. Epub 
      2021 Mar 30.